Veterinary Medicines

FATROXIMIN, odos purškalas

Authorised
  • Rifaximin
Download as PDF

Product identification

Medicine name:
FATROXIMIN, odos purškalas
Active substance:
  • Rifaximin
Target species:
  • Horse
  • Cattle
  • Sheep
  • Goat
  • Pig
  • Rabbit
  • Dog
  • Cat
Route of administration:
  • Cutaneous use

Product details

Active substance and strength:
  • Rifaximin
    0.50
    gram(s)
    /
    170.00
    gram(s)
Pharmaceutical form:
  • Cutaneous spray, suspension
Withdrawal period by route of administration:
  • Cutaneous use
    • Horse
      • Meat and offal
        0
        day
      • Milk
        0
        day
    • Cattle
      • Meat and offal
        0
        day
      • Milk
        0
        day
    • Sheep
      • Meat and offal
        0
        day
      • Milk
        0
        day
    • Goat
      • Meat and offal
        0
        day
      • Milk
        0
        day
    • Pig
      • Meat and offal
        0
        day
    • Rabbit
      • Meat and offal
        0
        day
    • Dog
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QD06AX11
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Lithuania
Available in:
  • Lithuania
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Fatro S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Fatro S.p.A.
Responsible authority:
  • State Food And Veterinary Service
Authorisation number:
  • LT/2/01/1285/001
Date of authorisation status change:

Documents

RV1285.pdf

Lithuanian (PDF)
Published on: 8/06/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."